Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20802304 | 0.83 | AGBL2 (0.35) | ASPHAGBL2PGK1PGK2COMT | |
| SCHEMBL22548075 | 0.81 | CYP2C9 (0.42) | HSD17B10ALDH1A1 | |
| SCHEMBL13073943 | 0.78 | UHRF1 (0.46) | ASPHAGBL2PGK1PGK2HPGD | |
| SCHEMBL26375202 | 0.77 | ASPH (0.35) | ASPHAGBL2PGK1PGK2HPGD | |
| SCHEMBL29956331 | 0.76 | ASPH (0.36) | ASPHAURKASYK | |
| SCHEMBL24858337 | 0.75 | NOS3 (0.56) | HPGDHSD17B10 | |
| SCHEMBL30503537 | 0.75 | PIK3R1 (0.36) | ASPHAGBL2COMTHPGDHSD17B10 | |
| SCHEMBL14392743 | 0.75 | AGBL2 (0.35) | ASPHAGBL2PGK1PGK2HPGD | |
| SCHEMBL29851068 | 0.75 | NOS3 (0.56) | HPGDHSD17B10 | |
| SCHEMBL12935347 | 0.75 | PIK3R1 (0.36) | ASPHAGBL2COMTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4511116-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | ASPH 3424/4885AURKA 4587/4885AGBL2 3238/4885 |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | ASPH 2612/4885AURKA 4217/4885AGBL2 3596/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | ASPH 2612/4885AURKA 4217/4885AGBL2 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.